Dexcom Inc. Stock
Dexcom Inc. Stock
A very strong showing by Dexcom Inc. today, with an increase of €3.16 (5.460%) compared to yesterday's price.
The stock is one of the favorites of our community with 39 Buy predictions and 1 Sell predictions.
With a target price of 79 € there is a positive potential of 29.85% for Dexcom Inc. compared to the current price of 60.84 €.
Our community identified positive and negative aspects for Dexcom Inc. stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Dexcom Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Dexcom Inc. in the next few years
Pros
?
M***** P*******
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Dexcom Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Dexcom Inc. | 5.460% | 5.442% | 6.662% | -19.863% | 6.141% | -38.384% | -17.505% |
| Zimmer Holdings | -1.680% | -0.759% | 0.513% | -23.155% | 1.977% | -32.174% | -40.137% |
| Baxter International | -4.620% | 1.779% | 5.960% | -39.843% | 6.064% | -58.477% | -73.810% |
| Stryker Corp. | -2.370% | 4.134% | 2.685% | -13.221% | 3.405% | 31.160% | 58.077% |
Comments
DexCom (NASDAQ:DXCM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Show more
Ratings data for DXCM provided by MarketBeat
DexCom (NASDAQ:DXCM) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating. They now have a $71.00 price target on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
DexCom (NASDAQ:DXCM) had its price target raised by analysts at Mizuho from $75.00 to $78.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
News
DexCom Stock Just Fell to a 5-Year Low. Is It a No-Brainer Buy at This Price?
It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you
1 Spectacular Growth Stock Down 20% to Buy Right Now, According to Wall Street
Since last year, DexCom (NASDAQ: DXCM) has faced a series of issues that have sunk its stock price. The medical device specialist's shares are down 20% over the trailing-12-month period and are
From Dividends to Growth: Why These 3 Stocks Stand Out in 2025
It's rare for an attractive dividend stock also to have growth potential. Most leading dividend distributors have moved past their high-growth days and have transitioned into stable, mature
